ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
5,967.84
-0.22%
US Tech 100
21,102.40
-0.27%
Dow Jones
42,206.82
0.08%
Brent Oil
76.125
0.00%
Bitcoin
103,486.95
0.16%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Lyell Immunopharma Inc (LYEL) Quote

Lyell Immunopharma Inc

Lyell Immunopharma Inc (LYEL)

NASDAQ
8.69
-0.89
(-9.29%)
Closed June 21 4:00PM
15 min delayed - Upgrade to Realtime
8.69
0.00
(0.00%)
After Hours: 5:32PM
15 min delayed - Upgrade to Realtime

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
8.69
Bid
8.79
Ask
9.83
Volume
229,048
8.52 Day's Range 9.8378
7.65 52 Week Range 45.424
Market Cap
128.682M
Previous Close
9.58
Open
9.63
Last Trade
11
@
8.79
Last Trade Time
Financial Volume
$ 2,104,803
VWAP
9.1894
Average Volume (3m)
637,551
Shares Outstanding
14,808,078
Dividend Yield
-
PE Ratio
-0.38
Earnings Per Share (EPS)
-23.16
Revenue
3.37M
Net Profit
-342.99M

About Lyell Immunopharma Inc

Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors). Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
lyell.com
Headquarters
Dover, Delaware, USA
Founded
-
Lyell Immunopharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LYEL. The last closing price for Lyell Immunopharma was $9.58. Over the last year, Lyell Immunopharma shares have traded in a share price range of $ 7.65 to $ 45.424.

Lyell Immunopharma currently has 14,808,078 shares outstanding. The market capitalization of Lyell Immunopharma is $141.86 million. Lyell Immunopharma has a price to earnings ratio (PE ratio) of -0.38.

Ask ADVFN Intelligence (AI)

LYEL Latest News

More News

Form 8-K - Current report
Edgar (US Regulatory)
June 17 2025
LYEL (-9.29%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
June 11 2025
LYEL (-9.29%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
June 11 2025
LYEL (-9.29%)

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
June 11 2025
LYEL (-9.29%)

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
June 11 2025
LYEL (-9.29%)

Form 8-K - Current report
Edgar (US Regulatory)
June 09 2025
LYEL (-9.29%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
May 13 2025
LYEL (-9.29%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.71-7.553191489369.410.968.691109049.80053731CS
40.495.97560975618.213.87.6540920010.44674232CS
12-3.12-26.418289585111.8113.87.656375519.09178522CS
26-3.804-30.446614374912.49415.6187.6585154211.0946789CS
52-32.71-79.009661835741.445.4247.65101093618.53253312CS
156-99.31-91.9537037037108174.87.65100969451.12427127CS
260-366.31-97.6826666667375396.87.6595019474.23113882CS

LYEL - Frequently Asked Questions (FAQ)

What is the current Lyell Immunopharma share price?
The current share price of Lyell Immunopharma is $ 8.69
How many Lyell Immunopharma shares are in issue?
Lyell Immunopharma has 14,808,078 shares in issue
What is the market cap of Lyell Immunopharma?
The market capitalisation of Lyell Immunopharma is USD 141.86M
What is the 1 year trading range for Lyell Immunopharma share price?
Lyell Immunopharma has traded in the range of $ 7.65 to $ 45.424 during the past year
What is the PE ratio of Lyell Immunopharma?
The price to earnings ratio of Lyell Immunopharma is -0.38
What is the cash to sales ratio of Lyell Immunopharma?
The cash to sales ratio of Lyell Immunopharma is 38.18
What is the reporting currency for Lyell Immunopharma?
Lyell Immunopharma reports financial results in USD
What is the latest annual turnover for Lyell Immunopharma?
The latest annual turnover of Lyell Immunopharma is USD 3.37M
What is the latest annual profit for Lyell Immunopharma?
The latest annual profit of Lyell Immunopharma is USD -342.99M
What is the registered address of Lyell Immunopharma?
The registered address for Lyell Immunopharma is 3500 S DUPONT HWY, DOVER, DELAWARE, 19901
What is the Lyell Immunopharma website address?
The website address for Lyell Immunopharma is lyell.com
Which industry sector does Lyell Immunopharma operate in?
Lyell Immunopharma operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NXTTNext Technology Holding Inc
$ 3.44
(158.65%)
13.84M
WHLRWheeler Real Estate Investment Trust Inc
$ 7.15
(109.06%)
52.35M
CTORCitius Oncology Inc
$ 2.63
(69.68%)
20.77M
LUCYInnovative Eyewear Inc
$ 3.52
(54.39%)
111.21M
LGCLLucas GC Ltd
$ 1.0407
(53.16%)
11.17M
NWGLNature Wood Group Ltd
$ 1.71
(-69.63%)
3.99M
ICUSeaStar Medical Holding Corporation
$ 0.351
(-64.05%)
21.9M
MBRXMoleculin Biotech Inc
$ 0.259999
(-55.40%)
16.84M
RGCRegencell Bioscience Holdings Ltd
$ 37.50
(-40.81%)
2.22M
CGTLCreative Global Technology Holdings Ltd
$ 1.4399
(-36.57%)
6.71M
HCTIHealthcare Triangle Inc
$ 0.0297
(12.08%)
583.72M
DFLIDragonfly Energy Holdings Corporation
$ 0.245
(12.39%)
334.37M
GNLNGreenlane Holdings Inc
$ 0.009
(-13.04%)
262.88M
NVDANVIDIA Corporation
$ 143.85
(-1.12%)
242.95M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 12.359
(-0.09%)
193.97M

LYEL Discussion

View Posts
jondoeuk jondoeuk 3 days ago
It will be interesting to see GILD's KITE-753 clinical data. The only difference between it (and KITE-363) is a reduced production time.

However, based on preclinical data, KITE-753 exhibited higher expression of both CARs and increased proportion of CCR7+/CD45RA+ T-cells* compared to the KITE-363 benchmark.

Also, KITE-753 exhibited enhanced cytokine production, enhanced proliferation, increased peripheral peak expansion, and superior antitumour efficacy compared to the KITE-363 benchmark.

* CCR7+/CD45RA+CD4+ of ~60% vs ~5%, and CCR7+/CD45RA+CD8+ of ~80% vs ~15%.

High circulating CCR7+ populations positively correlate with antitumour response https://www.nature.com/articles/s41591-020-1061-7
👍️0
jondoeuk jondoeuk 3 days ago
An update https://www.oncologypipeline.com/apexonco/lyell-takes-jj-and-gilead
👍️0
jondoeuk jondoeuk 2 months ago
An update on prizlon-cel

👍️0
jondoeuk jondoeuk 2 months ago
An update on CRGX https://www.fiercebiotech.com/biotech/cargo-jettisons-remaining-assets-and-90-workforce-it-looks-reverse-merger
👍️0
glenn1919 glenn1919 3 months ago
LYEL..................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
glens0 glens0 4 months ago
https://ih.advfn.com/stock-market/NASDAQ/lyell-immunopharma-LYEL/stock-news/95521325/form-4-statement-of-changes-in-beneficial-owners
👍️0
georgie18 georgie18 4 months ago
Yup...LYEL...🥳...Moving up nicely...
👍️0
glens0 glens0 4 months ago
$LYEL .7486
👍️0
georgie18 georgie18 4 months ago
LYEL...7008...Off the .56 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 32376

Friday, February 21, 2025 9:40:49 AM

Post#
32428
of 32525
LYEL...6868...🥳...Trying for Double Top Breakout here...Off the .56 Alert...

georgie18

Member Level
Re: georgie18 post# 674836

Thursday, February 20, 2025 2:04:23 PM

Post#
674950
of 675048
LYEL...66...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 32041

Wednesday, February 19, 2025 3:48:52 PM

Post#
32270
of 32375
LYEL...6145...Bullish Engulfing Reversal Candle...🥳

LYEL...639...🥳...Looking for $1 plus here...

georgie18

Member Level
Re: None

Thursday, February 13, 2025 4:20:43 PM

Post#
32007
of 32040
LYEL...56...🥳... https://schrts.co/XneECpDw...https://finance.yahoo.com/news/lyell-immunopharma-lyel-upgraded-strong-170012527.html

This is a Rigatoni Play ...one of the best Traders I have had the pleasure of knowing for many years...
👍️0
georgie18 georgie18 4 months ago
LYEL...6868...🥳...Trying for Double Top Breakout here...Off the .56 Alert...

georgie18

Member Level
Re: georgie18 post# 674836

Thursday, February 20, 2025 2:04:23 PM

Post#
674950
of 675048
LYEL...66...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 32041

Wednesday, February 19, 2025 3:48:52 PM

Post#
32270
of 32375
LYEL...6145...Bullish Engulfing Reversal Candle...🥳

LYEL...639...🥳...Looking for $1 plus here...

georgie18

Member Level
Re: None

Thursday, February 13, 2025 4:20:43 PM

Post#
32007
of 32040
LYEL...56...🥳... https://schrts.co/XneECpDw...https://finance.yahoo.com/news/lyell-immunopharma-lyel-upgraded-strong-170012527.html

This is a Rigatoni Play ...one of the best Traders I have had the pleasure of knowing for many years...
👍️0
georgie18 georgie18 4 months ago
LYEL...66...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 32041

Wednesday, February 19, 2025 3:48:52 PM

Post#
32270
of 32375
LYEL...6145...Bullish Engulfing Reversal Candle...🥳

LYEL...639...🥳...Looking for $1 plus here...

georgie18

Member Level
Re: None

Thursday, February 13, 2025 4:20:43 PM

Post#
32007
of 32040
LYEL...56...🥳... https://schrts.co/XneECpDw...https://finance.yahoo.com/news/lyell-immunopharma-lyel-upgraded-strong-170012527.html

This is a Rigatoni Play ...one of the best Traders I have had the pleasure of knowing for many years...
👍️0
georgie18 georgie18 4 months ago
LYEL...6145...Bullish Engulfing Reversal Candle...🥳

LYEL...639...🥳...Looking for $1 plus here...

georgie18

Member Level
Re: None

Thursday, February 13, 2025 4:20:43 PM

Post#
32007
of 32040
LYEL...56...🥳... https://schrts.co/XneECpDw...https://finance.yahoo.com/news/lyell-immunopharma-lyel-upgraded-strong-170012527.html

This is a Rigatoni Play ...one of the best Traders I have had the pleasure of knowing for many years...
👍️0
georgie18 georgie18 4 months ago
LYEL...639...🥳...Looking for $1 plus here...

georgie18

Member Level
Re: None

Thursday, February 13, 2025 4:20:43 PM

Post#
32007
of 32040
LYEL...56...🥳... https://schrts.co/XneECpDw...https://finance.yahoo.com/news/lyell-immunopharma-lyel-upgraded-strong-170012527.html

This is a Rigatoni Play ...one of the best Traders I have had the pleasure of knowing for many years...
👍️0
georgie18 georgie18 4 months ago
LYEL...56...🥳... https://schrts.co/XneECpDw...https://finance.yahoo.com/news/lyell-immunopharma-lyel-upgraded-strong-170012527.html

This is a Rigatoni Play ...one of the best Traders I have had the pleasure of knowing for many years...
👍️0
jondoeuk jondoeuk 5 months ago
There are other bi-specific CARs, including two by GILD's Kite, and at least one tri-specific in development as well.

CRGX's CRG-023 (IND cleared, PhI mid-year) is the first tri-specific CAR-T to express three independent CARs from a single vector, with each CAR having a distinct co-stim domain. One co-stim domain incorporates CD2 signaling, which has been designed to overcome immune-evasion mediated by the loss of CD58 https://ashpublications.org/blood/article/136/Supplement%201/53/470303/CD58-Aberrations-Limit-Durable-Responses-to-CD19

Novel CD19 and CD20 scFvs were selected for enhanced CAR performance and combined with the existing CD22 scFv used in firi-cel. These new binders are fully human to limit host-mediated rejection. The iterative engineering allowed for the selection of the optimal costimulatory domain configuration and optimal assemblage in the lentiviral vector used https://www.sciencedirect.com/science/article/pii/S0006497124047827
👍️0
jondoeuk jondoeuk 5 months ago
What they don't say is equally as important as what they do say.

Prizlon-cel, is a novel CD19/CD20 bispecific CAR-T. Of the 48 patients infused, 44 had LBCL. No patient experienced a DLT. CRS occurred in 93.8% of patients, with only one case of grade 3. ICANS occurred in 6.3% of patients, with no grade 3 or higher events. The ORR and complete response (CR) rates in all patients were 91.5% and 85.1%, respectively, and in LBCL patients, ORR was 90.7% with 86.0% CR. With median follow up of 30.0 months, median DOR, PFS, and OS were all not reached. The Kaplan-Meier estimate of 2-year DOR, PFS and OS rates were 66.0%, 62.6%, and 76.5%, respectively. https://ashpublications.org/blood/article/doi/10.1182/blood.2024026401/535112/A-phase-1-trial-of-prizloncabtagene-autoleucel-a

The company behind it has signed deals with both AstraZeneca and Janssen. The latter includes this CAR (and another targeting just CD20), which has been granted Regenerative Medicine Advanced Therapy and Fast Track designations by the FDA for the treatment of patients with R/R DLBCL. Now a PhI/II trial is ongoing https://clinicaltrials.gov/study/NCT05800977
👍️0
jondoeuk jondoeuk 5 months ago
An update https://www.biospace.com/press-releases/lyell-to-highlight-vision-for-its-next-generation-car-t-cell-therapy-pipeline-at-43rd-annual-jp-morgan-healthcare-conference

See slide 10 https://ir.lyell.com/static-files/96379999-4d8e-466b-a5d5-44f5f6f88583
👍️0
glenn1919 glenn1919 6 months ago
LYEL.................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 7 months ago
lyel..............................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 8 months ago
LYEL................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 8 months ago
As a reminder, the ORR was ~12.5% for LYL797. BMY's JCAR024 had an ORR of 5-6%, but was discontinued, while a Fred Hutch construct showed no responses.
👍️0
jondoeuk jondoeuk 8 months ago
An update https://www.globenewswire.com/news-release/2024/10/24/2969054/0/en/Lyell-Immunopharma-to-Acquire-ImmPACT-Bio-and-Prioritizes-its-Pipeline-to-Focus-on-Next-Generation-CAR-T-cell-Therapies.html

The webcast https://lyell-company-update-2024.open-exchange.net/registration

Slides https://ir.lyell.com/static-files/40d6bd34-9ad0-49dd-b816-4bda3bd53eb0
👍️0
glenn1919 glenn1919 8 months ago
LYEL..........................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 9 months ago
Preclinical data (Stim-R tech) https://www.nature.com/articles/s41598-024-72392-1
👍️0
glenn1919 glenn1919 10 months ago
LYEL..................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 1 year ago
(OT) Dr Restifo is Co-founder and Chief Scientist at Marble Therapeutics. From this: ''At Marble Therapeutics, he is working to figure out how to rewind the epigenetic clock on these cells, using any means possible. The company started out with a focus on skin rejuvenation, adds CEO Denitsa Milanova, but expanded to also work on adoptive cell therapy to prove their platform works.'' https://web.archive.org/web/20231218233715/https://www.nature.com/articles/d41573-023-00206-6

They have a license for TIL plus a neoantigen vaccine https://www.federalregister.gov/documents/2024/02/07/2024-02491/prospective-grant-of-an-exclusive-patent-license-vaccine-augmented-adoptive-cell-therapy-for-the

Preclinical data on the vaccine https://jitc.bmj.com/content/11/Suppl_1/A418
🎯 1 👍️ 1
glenn1919 glenn1919 1 year ago
LYEL.....................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 1 year ago
LYEL active in the Gaucho session

👍️0
jondoeuk jondoeuk 1 year ago
Tempting but I will remain on the sidelines.
👍️0
Monksdream Monksdream 1 year ago
LYEL under $3
👍️0
glenn1919 glenn1919 1 year ago
LYEL..................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 2 years ago
They could be working on this https://ash.confex.com/ash/2023/webprogram/Paper182417.html
👍️0
jondoeuk jondoeuk 2 years ago
Upcoming https://www.globenewswire.com/news-release/2023/09/27/2750444/0/en/Lyell-Immunopharma-Announces-the-Acceptance-of-Six-Abstracts-for-Presentation-at-2023-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html
👍️0
Monksdream Monksdream 2 years ago
LYEL new 52 week low
👍️0
jondoeuk jondoeuk 2 years ago
LYL119 https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=13739
👍️0
jondoeuk jondoeuk 2 years ago
Preclinical data from another group (LYL119 will be NR4A3-deficient) https://www.biorxiv.org/content/10.1101/2023.04.21.537841v1.full
👍️0
glenn1919 glenn1919 2 years ago
LYEL..........................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 3 years ago
The FDA has cleared an IND for LYL845. The PhI trial will initially enroll patients with relapsed and/or refractory metastatic or locally advanced melanoma and subsequently expand into NSCLC and CRC. Initial data presentation is expected in 2024.
👍️0
jondoeuk jondoeuk 3 years ago
SITC titles

NR4A3 gene editing and c-Jun overexpression synergize to limit exhaustion and enhance functional activity of ROR1 CAR T cells in vitro and in vivo

Engineering potent CAR T-cell therapies by controlling T-cell activation signaling parameters using the Stim-R™ technology, a programmable synthetic cell-signaling platform

The Epi-R™ technology produces a polyclonal TIL product (LYL845) with diverse tumor-reactive clones that have stem-like qualities and anti-tumor function

The Epi-R™ technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity

Increased potency and functional persistence in vitro of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-R™ genetic reprogramming technology
👍️0
NY1972 NY1972 3 years ago
recent technical advances using culture conditions with IL-7/IL-15 and
the addition of IL-21 may enhance the enrichment for TSCM cells
in the final CART product (74–76), which can be further increased
with the addition of drugs blocking T-cell differentiation, such as
glycogen synthase-3 inhibitors (77). Nevertheless, robust clinical grade protocols for generating TSCM-enriched CART products
have not been developed so far. Recently, a few CART19 clinical
trials for DLBCL have been conducted in which CART products
were manufactured from CD62L+ isolated T cells to generate
cellular products enriched for TCM cells (21, 78); however, due to
prolonged culture conditions, enrichment for TSCM and TCM
subsets in the infused product could not be demonstrated

https://www.frontiersin.org/articles/10.3389/fimmu.2022.904497/full
👍️0
jondoeuk jondoeuk 3 years ago
The AEs from the LD chemo*. I expect more data (dose expansion is ongoing) from them at ASH. As for NVS, a pivotal trial is planned and DL2 (12.5M) is the recommended dose.

* Some very early clinical data testing an anti-GD2 CAR-T with constitutive signaling from an engineered IL-7 receptor
👍️0
NY1972 NY1972 3 years ago
Thanks for the link.
Most commonly reported grade 3/4 AEs were neutrophil count decrease (6/9, 67%), anemia (5/9, 56%), thrombocytopenia (2/9,22%), platelet count decrease (2/9, 22%) and no infection was reported. Complete response rate(CRR) was 78%

Compared to T-Charge
http://www.koreabiomed.com/news/articleView.html?idxno=12767

👍️0
jondoeuk jondoeuk 3 years ago
For Epi-R, they use media with high concentrations of potassium (as well as multiple cytokines). As for that, T-Charge or BE, I think a product with mostly ''stem-like'' cells and additional edits will be needed. But it doesn't have to be the latter, as shRNA can be used. Here are some clinical data on an anti-CD19 CAR-T with knock-down of both PD-1 and TIGIT https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7522
👍️0
NY1972 NY1972 3 years ago
Which will perform better ? BE with 7,8 edits on many genes, Epi secret sauce
or T-Charge which seems to add a CAR only to starting material in order to retain CD4/CD8 ratio.
YTB323 CAR-T cell products generated via this novel expansionless manufacturing process retained the immunophenotype of the input leukapheresis materia
👍️0
jondoeuk jondoeuk 3 years ago
That depends. Typically, the more the cells expand during manufacturing, the more they differentiate. In the case of ALLO, it seems most are effector memory (manufacturing time is ~19 days and there are a number of steps involved). LYEL refer to this as the expansion/quality paradox. With Epi-R, they have shown they can expand TCR-T cells up to 18 billion by day ten. In addition, these cells are over 94% viable and maintain their ''stem-like'' qualities.
👍️0
NY1972 NY1972 3 years ago
Do you need Epigenetic Reprogramming if pts can be treated with healthy, young donor T cells?
👍️0
jondoeuk jondoeuk 3 years ago
ISSCR poster https://ir.lyell.com/static-files/971404cb-28eb-46fc-839f-b20735899373
👍️0
jondoeuk jondoeuk 3 years ago
Posters https://ir.lyell.com/static-files/d3a3d05c-1b39-4092-bf82-a486933bc268

https://ir.lyell.com/static-files/6014be8d-4e9d-499b-a496-513d2962f3e4
👍️0
jondoeuk jondoeuk 3 years ago
1115: Epigenetic Reprogramming (Epi-R™) Yields T-Cell Receptor Products with Improved Stemness, Metabolic Fitness, and Functional Activity in the Presence of Persistent Antigen Exposure https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=2014

661: Preclinical Development of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced with Genetic and Epigenetic Reprogramming for Solid Tumors https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1597
👍️0
jondoeuk jondoeuk 3 years ago
GSK has updated the master protocol for their next generation constructs to include a third arm with GSK4427296 https://clinicaltrials.gov/ct2/show/NCT04526509

This uses Epi-R.
👍️0

Your Recent History

NASDAQ
LYEL
Lyell Immunopharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN Ltd - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads